PSI Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

PSI Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-600	Closed	-$9.97K	–	117
2025 Q1	$9.97K	Hold	600	–	–	﹤0.01%	449
2024 Q4	$11K	Hold	600	–	–	﹤0.01%	510
2024 Q3	$9.23K	Hold	600	–	–	﹤0.01%	550
2024 Q2	$9.75K	Hold	600	–	–	﹤0.01%	520
2024 Q1	$11.1K	Hold	600	–	–	﹤0.01%	472
2023 Q4	$18.8K	Hold	600	–	–	0.01%	426
2023 Q3	$12.5K	Hold	600	–	–	0.01%	461
2023 Q2	$14.4K	Hold	600	–	–	0.01%	441
2023 Q1	$11.3K	Hold	600	–	–	0.01%	413
2022 Q4	$9.55K	Sell	600 -100	-14%	-$1.56K	0.01%	435
2022 Q3	$11K	Hold	700	–	–	0.01%	406
2022 Q2	$10K	Hold	700	–	–	﹤0.01%	455
2022 Q1	$17K	Hold	700	–	–	0.01%	387
2021 Q4	$16K	Hold	700	–	–	0.01%	431
2021 Q3	$12K	Buy	+700	New	+$13.5K	0.01%	462
2020 Q1	–	Sell	-850	Closed	-$36K	–	111
2019 Q4	$36K	Buy	+850	New	+$37K	0.02%	301

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

PSI Advisors's ACAD Position: Q2 2025 in Review

PSI Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 600 shares — an estimated $9.97K sold.

PSI Advisors first reported a position in ACAD in Q4 2019 and held it in 16 quarters. The position peaked at $36K in Q4 2019. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

PSI Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
PSI Advisors sold 600 Acadia Pharmaceuticals shares in Q2 2025, an estimated $9.97K.
PSI Advisors first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 16 quarters.
PSI Advisors's Acadia Pharmaceuticals position peaked at $36K in Q4 2019.
311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on PSI Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.